New FDA Approval: Osimertinib (TAGRISSO®) Combined with Chemotherapy for Treating EGFR-Mutated NSCLC Non-Small Cell Lung Cancer 4 Mins Read3 On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name…
